

Listing of Claims

1-43 (Canceled)

44. (Currently amended) A genetically modified cell comprising, a polynucleotide encoding an antibody or fragment thereof, and a promoter sequence controlling expression of the polynucleotide in the cell, wherein the polynucleotide is expressed and the cell expresses and secretes the antibody or fragments thereof into the blood circulation of a subject mammal following transplant of the cell, and wherein the cell is a cell not specialized for the natural production of antibodies non-plasmocyte mammalian cell suitable for introduction into a subject in that the genetically modified cell does not cause disease in the subject following transplantation.

45. (Previously presented) The genetically modified cell of claim 44, wherein the cell is selected from the group consisting of keratinocytes, hepatocytes, skin fibroblasts, myoblasts, endothelial cells and hematopoietic stem cells.

46. (Canceled)

47. (Currently amended) The genetically modified cell of claim 44, wherein the cell is capable of differentiating into a tissue but retains the ability to ~~express~~ secrete the antibody.

48. (Canceled)

49. (Previously presented) The genetically modified cell of claim 44, wherein the antibody is detectable in the blood of the subject mammal following transplant of the cell.

50. (Previously presented) The genetically modified cell of claim 44, wherein the antibody is detectable in the blood of the subject mammal for at least four months following transplant of the cell.

51. (Currently amended) The genetically modified cell of claim 44, wherein ~~the antibody is secreted into the blood of a subject mammal having received the cell, and~~ the antibody is detectable in the blood of the subject mammal at a concentration exceeding 100 ng/ml of serum.

52. (Currently amended) A method of delivering an antibody to a subject mammal comprising, transplanting ~~obtaining~~ a genetically modified cell ~~further~~ comprising a polynucleotide encoding an antibody or fragment thereof, and a promoter sequence controlling expression of the polynucleotide in the cell, wherein the polynucleotide is expressed and the cell expresses and secretes the antibody or fragment fragments thereof into the blood circulation of the subject mammal, ~~and transplanting the genetically modified cell into the subject, and wherein the cell is a cell not specialized for the natural production of antibodies non-plasmocyte mammalian cell suitable for introduction into a subject in that the genetically modified cell does not cause disease in the subject following transplantation.~~

53. (Previously presented) The method of claim 52, wherein the cell is selected from the group consisting of keratinocytes, hepatocytes, skin fibroblasts, myoblasts, endothelial cells and hematopoietic stem cells.

54. (Canceled)

55. (Currently amended) The method of claim 52, wherein the cell is capable of differentiating into a tissue but retains the ability to ~~express~~ secrete the antibody.

56. (Canceled)

57. (Currently amended) The method of claim 52, wherein the antibody is detectable in the blood of the subject mammal ~~following transplant of the cell.~~

58. (Previously presented) The method of claim 52, wherein the antibody is detectable in the blood of the subject mammal for at least four months following transplant of the cell.

59. (Currently amended) The method of claim 52, wherein ~~the antibody is secreted into the blood of a subject mammal having received the cell, and~~ the antibody is detectable in the blood of the subject mammal at a concentration exceeding 100 ng/ml of serum..